Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Non SARS-Cov-2 Kits > BCMA > EP-118

BCMA [Biotinylated] : BAFF Inhibitor Screening Chemiluminescence Assay Kit

For research use only.
IDComponentsSize
EP118-C01High-bind Plate1 plate
EP118-C02Human BAFF40 μg
EP118-C03Biotinylated Human BCMA10 μg
EP118-C04Anti-BCMA Neutralizing Antibody40 μg
EP118-C05Streptavidin-HRP10 μg
EP118-C06Coating Buffer12 mL
EP118-C0710xWashing Buffer 50 mL
EP118-C08Blocking Buffer50 mL
EP118-C09-AELISA Femto Substrate A6 mL
EP118-C09-BELISA Femto Substrate B6 mL
  • Background
    TNFRSF17 is a member of the TNF-receptor family, known as tumor necrosis factor receptor superfamily member 17, also known as B cell maturation antigen (BCMA or BCM) or CD269. It is a protein encoded by TNFRSF17 gene.  The receptor is expressed on the surface of B lymphocytes and plasma cells and is a marker protein of B lymphocyte maturation.The main ligands of BCMA are BAFF and APRIL. BCMA combined with BAFF could activate the classical and non-classical NF-κB and JNK signaling pathways, up-regulate the expression of anti-apoptotic protein and down-regulate the expression of pro-apoptotic protein. When BCMA binds to APRIL, the expression level of immune checkpoint is up-regulated, creating an immunosuppressed bone marrow microenvironment.
  • Application
    This kit is developed for screening for inhibitors of human BCMA binding to human BAFF.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening Assay kit is designed to facilitate the identification and characterization of new BCMA pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human BCMA to immobilized human BAFF in a functional chemiluminescence assay. Briefly, we provide you with a human Biotinylated BCMA protein, a human BAFF protein, an anti-BCMA neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human BAFF.

    b) Add your molecule of interest to the tests.

    c) Add human BCMA-Biotin to bind the coated human BAFF.

    d) Add Streptavidin-HRP followed by luminol .

    Finally, the half maximal inhibitory concentration (IC50) of your compound to BCMA: BAFF binding will be determined by comparing RLU readings among different experimental groups.

Typical Data
 BCMA ELISA

INHIBITION OF BCMA [BIOTINYLATED]: BAFF BINDING BY ANTI-BCMA NEUTRALIZING ANTIBODY
Serial dilutions of Anti-BCMA Neutralizing antibody (Catalog # EP118-C04) (1:1 serial dilution, from 20 μg/mL to 0.02μg/mL) was added into Biotinylated BCMA: BAFF binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $650.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:2 Details
  • Number of Drugs in Clinical Trials:58 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message